7月21日 - ** 券商Truist将制药公司百健BIIB.O的评级从 "买入 "下调至 "持有"，并将目标价从199美元下调至142美元。
** 新的PT意味着该股较上次收盘价有13.6%的上涨空间
** Truist表示，下调评级的原因是百健公司现有产品的增长前景疲软，而且没有低风险的新药在研发中。
** 券商不再看好百健的阿尔茨海默氏症药物机会，预计Leqembi的增长有限
** 预计Zurzuvae的增长有限，认为Skyclarys的销售已经达到顶峰，并称百健公司的后期管线被视为高风险药物
** 截至上一交易日收盘，BIIB股价累计下跌18.3%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.